CD19 and neoplasm: Moreover, the lymphodepleted NHP model should be further evaluated by using other CAR‐T cells which are known to exhibit acceptable off‐tumor toxicity (i.e. CD19‐CAR‐T cells) before the validation and application of this model for toxicity assessment.